Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caraco Pharmaceutical Laboratories, a subsidiary of Sun Pharma and a developer and distributer of generic pharmaceuticals, has launched 50mg and 100mg oxaliplatin injections for the treatment of colon and rectal cancers.
Subscribe to our email newsletter
The injections, which are therapeutically equivalent to Eloxatin from Sanofi-Aventis, received approval from the FDA for Sun Pharma’s abbreviated new drug application (ANDA).
Eloxatin is a registered trademark of Sanofi Aventis US, according to Caraco Pharmaceutical release. Teva Pharmaceutical Industries also sells a generic version of the drug, which is aimed at colon and rectal cancers.
Caraco said that it sells approximately $1.3bn worth of Oxaliplatin injections in the US.